Leprosy transmission and mucosal immunity: Towards eradication?

Leprosy Review

Volumn 69, Issue 2, 1998, Pages 112-121

  Cree, I A ^a   Smith, W Cairns ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEPROSTATIC AGENT;

DISEASE COURSE; DISEASE TRANSMISSION; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; LEPROSY; MUCOSA; MYCOBACTERIUM LEPRAE; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW;

EID: 7344260775     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.19980011     Document Type: Review

References (60)

1. World Health Organisation. Progress towards the elimination of leprosy as a public health problem. Weekly Epidemiol Rec. 1996; 71: 149-156.
2. Editorial. Leprosy beyond the year 2000. Lancet, 1998; 350: 1717.
3. Klatser PR, van Beers S, Madjid B, Day R, de Wit MYL. Detection of Mycobacterium leprae nasal carriage in a leprosy endemic population. J Clin Microbiol. 1993; 31: 2947.
4. Hatta H, van Beers SM, Madjid B, de Wit MYL, Klatser PR. Distribution and persistence of Mycobacterium leprae nasal carriage among a population in which leprosy is endemic in Indonesia. Trans R Soc Trop Med Hyg. 1995; 89: 381-385.
5. van Beers SM, de Wit MYL, Klatser PR. The epidemiology of Mycobacterium leprae: recent insight. FEMS Microbiol Lett. 1996; 136: 221-230.
6. Godal T, Negassi K. Subclinical infection in leprosy. Brit Med J. 1973; 3: 557-559.
7. Cree IA, Smith WCS, Rees RJW, Beck JS. The influence of anti-mycobacterial chemotherapy on delayed hypersensitivity skin-test reactions in leprosy patients. Lepr Rev, 1988; 59: 145-151.
8. Cree IA, Smith WCS, Beck JS. Serum antibody responses to mycobacteria in leprosy patients and their contacts. Lepr Rev. 1988, 59: 317-328.
9. Ramaprasad P, Fernando A, Madhale S, Rao JR, Edward VK, Samson PD, Klatser PR, de Wit MYL, Smith WCS, Cree IA. Transmission and protection in leprosy: indications of the role of mucosal immunity. Lepr Rev. 1997; 68: 301-315.
10. Barton RPE, Hogerzeil LM, McDougall AC. Borderline-tuberculoid leprosy with a lepromatous nodule of the nasal mucosa: a case report. Lepr India, 1980; 52: 114-118.
11. Rao PS, Karat AB, Kaliaperumal VG, Karat S. Transmission of leprosy within households. Int J Lepr, 1975; 43: 45-54.
12. Noordeen SK. The epidemiology of leprosy. In: Leprosy. RC Hastings, ed. Churchill Livingstone, Edinburgh. 1985: 15-30.
13. Baumgart KW, Britton WJ, Mullins RJ, Basten A, Barnetson RS. Subclinical infection with Mycobacterium leprae - a problem for leprosy control strategies. Trans R Soc Trop Med Hyg, 1993; 87: 412-415.
14. Cree IA, Sharpe S, Sturrock NDC, Cochrance IH, Dawlako EC, Smith WCS, Beck JS. Mucosal immunity to mycobacteria in leprosy patients and their contacts. Lepr Rev, 1988; 59: 309-316.
15. Davey TF, Rees RJW. The nasal discharge in leprosy; clinical and bacteriological aspects. Lepr Rev. 1974; 45: 121-134.
16. Kazda J, Ganapati R, Revankar C, Buchanan TM, Young DB, Irgens LM. Isolation of environment-derived Mycobacterium leprae from soil in Bombay. Lepr Rev, 1986; 57: 201-208.
17. Desikan KV, Sreevatsa. Extended studies on the viability of Mycobacterium leprae outside the human body. Lepr Rev, 1995; 66: 287-295.
18. Pedley JC. Composite contact smears: a method of demonstrating the non-emergence of Mycobacterium leprae from intact lepromatous skin. Lepr Rev, 1970; 41: 31-43.
19. Pedley JC. Summary of the results of a search of the skin surface for Mycobacterium leprae. Lepr Rev, 1970; 41: 167-168.
20. de Wit MYL., Douglas JT, McFadden J, Klatser PR. Polymerase chain reaction for detection of Mycobacterium leprae in nasal swab specimens. J Clin Microbiol, 1993; 31: 502-506.
21. Fallen MJ, McDermott RD.How might Mycobacterium leprae enter the body? Lepr Rev, 1986; 57: 289.
22. McDermott-Lancaster RD, McDougall AC. Mode of transmission and histology of M. leprae infection in nude mice. Int J Exp Pathol, 1990; 71: 689-700.
23. Job CK, Baskaran B, Jayakumar J, Aschoff M. Histopathologic evidence to show that indeterminate leprosy may be a primary lesion of the disease. Int J Lepr, 1997; 65: 443-449.
24. Job CK, Drain V, Truman R, Deming AT, Sanchez RM, Hastings RC. The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies to PGL-1. Ind J Lepr, 1992; 64: 137-151.
25. Narayanan E, Sreevatsa, Kirchheimer WF, Bedi BM. Transfer of leprosy bacilli from patients to mouse footpads by Aedes aegypti. Lepr Ind, 1977; 49: 181-186.
26. Barton RPE. A clinical study of the nose in lepromatous leprosy. Lepr Rev, 1974; 45: 135-144.
27. Barton RPE, Rees RJW, McDougall AC, Ellard GA. The nose in lepromatous leprosy: bacteriological and histological studies of patients treated with dapsone monotherapy for varying periods of time. Int J Lepr, 1979; 50: 58-67.
28. Green CA, Katoch VM, Desikan KV. Quantitative estimation of Mycobacterium leprae in exhaled nasal breath. Lepr Rev, 1983; 54: 337-340.
29. Chacko CJG, Bhanu T, Victor V, Alexander R, Taylor PM, Job CK. The significance of changes in the nasal mucosa in indeterminate, tuberculoid and borderline leprosy. Lepr Ind. 1979; 51: 8-22.
30. Pedley JC. The nasal mucus in leprosy. Lepr Rev, 1973; 44: 33-35.
31. Rees RJW, McDougall AC, Weddell AGM. The nose in mice with experimental human leprosy. Lepr Rev, 1974; 45: 112-120.
32. Myrvang B, Godal T, Feek CM, Ridley DS, Samuel DD. Immune response to Mycobacterium leprae in indeterminate leprosy patients. Acta Pathol Microbiol Scand [B], 1973; 81: 615-620.
33. Bjune G, Closs O, Barnetson RStC. Early events in the host-parasite relationship and immune response in clinical leprosy: its possible importance for leprosy control. Clin Exp Immunol, 1983; 54: 289-297.
34. Lucas SB, Cree IA. Multisystem disease. In: Pathology, IA Cree, ed., Chapman & Hall, London, 1997: 150-155.
35. Grange JM. Mycobacteria and human disease. Edward Arnold Publishers Ltd, London, 1988: 142-152.
36. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol, 1995; 13: 151-177.
37. Ramaprasad P, Cree IA, Oluwole M, Samson PD. Development of a mucosal challenge test for leprosy using leprosin A. J Immunol Methods. 1995; 188: 239-246.
38. Allardyce RA, Bienenstock J. The mucosal immune system in health and disease with an emphasis on parasitic infection. Bull WHO, 1984; 62: 7-25.
39. Amy M, Kelly-Hatfield P, Lamm ME, Phillips-Quagliata JM. T-cell help for the IgA response: the function of T-cells from different lymphoid organs in regulating the proportions of plasma cells expressing various isotypes. Cell Immunol, 1984; 89: 95-112.
40. Abe M, Minagawa F, Yoshino Y, Itoh M. Immunoglobulin levels and antibody titers in nasal secretions versus serum of leprosy patients. Int J Lepr 1974; 42: 508 (Abstract).
41. Abe M, Yoshino Y, Minagawa F, Miyaji I, Sampoonachot P, Ozawa T, Sakamoto Y, Saito T, Saikawa K. Salivary immunoglobulins and antibody activities in leprosy. Int J Lepr, 1984; 52: 343-350.
42. Abe M, Miyaji I, Okushita T, Minagawa F, Yoshino Y, Sakamoto Y, Saikawa K. Anti-mycobacterial antibodies in saliva. Lepr Rev. 1986; 57: 213-223.
43. Bothamley GH, Cree IA. Antibody (IgA) specificity in leprosy. In: Advances in mucosal immunology (Proceedings of the Vth International Congress of Mucosal Immunology 1989), TT MacDonald, SJ Challacombe, PW Bland, CR Stokes, RV Heatley & AM Mowat, eds. Kluwer Academic Publishers, Dordrecht, Netherlands, 1990: 493-494.
44. Huang-CL. The transmission of leprosy in man. Int J Lepr. 1980; 48: 309-318.
45. Davey TF. A day in the life of Yeeranna - a cautionary tale. Lepr Rev, 1978; 49: 269-274.
46. Irgens LM. Leprosy in Norway - an epidemiological study based on a national patient registry. Lepr Rev. 1980; 51: 1-130.
47. Convit J, Sampson C, Zuniga M, Smith PG, Plata J, Silva J, Molina J, Pinardi ME, Bloom BR, Salgado A. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet, 1992; 339: 446-450.
48. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet, 1996; 348: 17-24.
49. Brechet RA. Chemoprophylaxis with DDS, mainly in children: a short trial. Lepr Rev, 1965; 36: 143-144.
50. Guinto RS. Chemoprophylaxis and BCG vaccination against leprosy. Int J Lepr, 1966; 34: 313-316.
51. Long ER. The chemoprophylaxis of mycobacterial diseases. Int J Lepr, 1966; 34: 65-67.
52. Noordeen SK, Neelan PN. Value of dapsone as a chemoprophylactic agent against leprosy (abstract IA8). In: Proceedings of the XI International Leprosy Congress, Mexico City, 1984: 4.
53. Neelan PN, Sirumban P, Sivaprasad N. Limited duration acedapsone prophylaxis in leprosy. Ind J Lepr, 1986; 58: 251-256
54. Sloan NR, Worth RM, Jano B, Fasal P, Shephard CC. Repository acedapsone in leprosy chemoprophylaxis and treatment. Lancet, 1971; 2: 525-526.
55. Sloan NR, Worth RM, Jano B, Fasal P, Shepard CC. Acedapsone in leprosy chemoprophylaxis: field trial in three high-prevalence villages in Micronesia. Int J Lepr, 1972; 40: 40-47.
56. World Health Organisation. Strategy of leprosy control. WHO Chronicle, 1978; 32: 193-199.
57. Russell DA, Worth RM, Jano B, Fasal P, Shephard CC. Acedapsone in the prevention of leprosy: field trial in three high prevalence villages in Micronesia. Am J Trop Med Hyg, 1979; 28: 559-563.
58. Cartel JL, Chanteau S, Boutin JP, Taylor R, Plichart R, Roux J, Celerier P, Grosset JH. Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of 25 mg per kg rifampin. Int J Lepr, 1989; 57: 810-816
59. Cartel JL, Chanteau S, Glaziou P, Roux JF, Grosset J. Five year evaluation of a program of chemoprophylaxis for leprosy using a single dose of 25 mg/kg rifampicin. Int J Lepr, 1993; 61: 61A.
60. John, TJ. Leprosy in the year 2000. Lancet, 1998; 351: 756.